TY - JOUR
T1 - Measurement of lysosomal enzyme activities
T2 - A technical standard of the American College of Medical Genetics and Genomics (ACMG)
AU - ACMG Laboratory Quality Assurance Committee
AU - Strovel, Erin T.
AU - Cusmano-Ozog, Kristina
AU - Wood, Tim
AU - Yu, Chunli
N1 - Publisher Copyright:
© 2021 American College of Medical Genetics and Genomics
PY - 2022/4
Y1 - 2022/4
N2 - Assays that measure lysosomal enzyme activity are important tools for the screening and diagnosis of lysosomal storage disorders (LSDs). They are often ordered in combination with urine oligosaccharide and glycosaminoglycan analysis, additional biomarker assays, and/or DNA sequencing when an LSD is suspected. Enzyme testing in whole blood/leukocytes, serum/plasma, cultured fibroblasts, or dried blood spots demonstrating deficient enzyme activity remains a key component of LSD diagnosis and is often prompted by characteristic clinical findings, abnormal newborn screening, abnormal biochemical findings (eg, elevated glycosaminoglycans), or molecular results indicating pathogenic variants or variants of uncertain significance in a gene associated with an LSD. This document, which focuses on clinical enzyme testing for LSDs, provides a resource for laboratories to develop and implement clinical testing, to describe variables that can influence test performance and interpretation of results, and to delineate situations for which follow-up molecular testing is warranted.
AB - Assays that measure lysosomal enzyme activity are important tools for the screening and diagnosis of lysosomal storage disorders (LSDs). They are often ordered in combination with urine oligosaccharide and glycosaminoglycan analysis, additional biomarker assays, and/or DNA sequencing when an LSD is suspected. Enzyme testing in whole blood/leukocytes, serum/plasma, cultured fibroblasts, or dried blood spots demonstrating deficient enzyme activity remains a key component of LSD diagnosis and is often prompted by characteristic clinical findings, abnormal newborn screening, abnormal biochemical findings (eg, elevated glycosaminoglycans), or molecular results indicating pathogenic variants or variants of uncertain significance in a gene associated with an LSD. This document, which focuses on clinical enzyme testing for LSDs, provides a resource for laboratories to develop and implement clinical testing, to describe variables that can influence test performance and interpretation of results, and to delineate situations for which follow-up molecular testing is warranted.
KW - Enzyme assays
KW - Lysosomal enzymes
KW - Lysosomal storage disorders
KW - Mucopolysaccharidosis
KW - Sphingolipidoses
UR - http://www.scopus.com/inward/record.url?scp=85127925666&partnerID=8YFLogxK
U2 - 10.1016/j.gim.2021.12.013
DO - 10.1016/j.gim.2021.12.013
M3 - Article
C2 - 35394426
AN - SCOPUS:85127925666
SN - 1098-3600
VL - 24
SP - 769
EP - 783
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 4
ER -